Search This Blog

Wednesday, January 2, 2019

Insmed initiated at Canaccord


Insmed initiated with a Buy at Canaccord. Canaccord analyst Dewey Steadman initiated Insmed with a Buy rating as he views the launch of Arikayce positively given the severe unmet need in nontuberculous mycobacterial lung disease and the potential for the drug to become core to the NTM treatment paradigm over time. He believes Insmend is well positioned as a specialty play and thinks the company has been unfairly caught up in broader infectious disease market meltdown as several antibiotic companies have disappointed investors. Steadman has a $20 price target on Insmed shares.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.